[{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"5-HT1F receptor","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Daiichi Sankyo","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Akums Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Akums Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Akums Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Akums Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Eli Lilly \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eli Lilly \/ Not Applicable"},{"orgOrder":0,"company":"Ildong Pharmaceutical","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lasmiditan","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Ildong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Ildong Pharmaceutical \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Ildong Pharmaceutical \/ Eli Lilly"}]

Find Clinical Drug Pipeline Developments & Deals for Lasmiditan

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Conjugates Summit
Not Confirmed
Conjugates Summit
Not Confirmed

Details : Reyvow-Generic (lasmiditan hemisuccinate) belongs to the “selective serotonin receptor agonists” class of medications and is specifically designed to alleviate the symptoms associated with migraine.

Product Name : Reyvow-Generic

Product Type : Small molecule

Upfront Cash : Not Applicable

January 05, 2024

Lead Product(s) : Lasmiditan

Therapeutic Area : Neurology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

02

Conjugates Summit
Not Confirmed
Conjugates Summit
Not Confirmed

Details : Reyvow (lasmiditan hemisuccinate) is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.

Product Name : Reyvow

Product Type : Small molecule

Upfront Cash : Not Applicable

August 25, 2022

Lead Product(s) : Lasmiditan

Therapeutic Area : Neurology

Highest Development Status : Approved

Sponsor : Eli Lilly

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

03

European Coatings Show
Not Confirmed
European Coatings Show
Not Confirmed

Details : Rayvow will be available as 50 mg, 100 mg and 200 mg film-coated tablets. The active substance of Rayvow is lasmiditan, a 5-hydroxytriptamine 1F (5-HT1F) receptor agonist (ATC code: N02CC), effecting a decrease of neuropeptide release and an inhibition o...

Product Name : Reyvow

Product Type : Small molecule

Upfront Cash : Not Applicable

June 23, 2022

Lead Product(s) : Lasmiditan

Therapeutic Area : Neurology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

04

Conjugates Summit
Not Confirmed
Conjugates Summit
Not Confirmed

Details : Reyvow (lasmiditan hemisuccinate) is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.

Product Name : Reyvow

Product Type : Small molecule

Upfront Cash : Not Applicable

January 21, 2022

Lead Product(s) : Lasmiditan

Therapeutic Area : Neurology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

05

European Coatings Show
Not Confirmed
European Coatings Show
Not Confirmed

Details : Under the agreement, Eli Lilly Japan will hold authorisation for marketing lasmiditan succinate, similar to the humanized anti-CGRP monoclonal antibody Emgality (galcanezumab), and Daiichi Sankyo will take charge of its distribution and sales after marke...

Product Name : Reyvow

Product Type : Small molecule

Upfront Cash : Undisclosed

August 30, 2021

Lead Product(s) : Lasmiditan

Therapeutic Area : Neurology

Highest Development Status : Approved

Sponsor : Daiichi Sankyo

Deal Size : Undisclosed

Deal Type : Collaboration

blank

06

Conjugates Summit
Not Confirmed
Conjugates Summit
Not Confirmed

Details : Reyvow (lasmiditan hemisuccinate) belongs to the “selective serotonin receptor agonists” class of medications and is specifically designed to alleviate the symptoms associated with migraine headaches.

Product Name : Reyvow

Product Type : Small molecule

Upfront Cash : Not Applicable

October 06, 2020

Lead Product(s) : Lasmiditan

Therapeutic Area : Neurology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

07

Next-Gen Conjugates
Not Confirmed
Next-Gen Conjugates
Not Confirmed

Details : Adults who took REYVOW C-V for their migraine attacks at doses of 100 mg or 200 mg had 3.8 and 4.6 times greater odds, respectively, of achieving pain freedom at 2 hours compared to those taking placebo, according to results from the recently completed P...

Product Name : Reyvow

Product Type : Small molecule

Upfront Cash : Not Applicable

September 11, 2020

Lead Product(s) : Lasmiditan

Therapeutic Area : Neurology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank

08

Conjugates Summit
Not Confirmed
Conjugates Summit
Not Confirmed

Details : Reyvow (lasmiditan hemisuccinate) belongs to the “selective serotonin receptor agonists” class of medications and is specifically designed to alleviate the symptoms associated with migraine headaches.

Product Name : Reyvow

Product Type : Small molecule

Upfront Cash : Not Applicable

January 31, 2020

Lead Product(s) : Lasmiditan

Therapeutic Area : Neurology

Highest Development Status : Approved

Sponsor : Not Applicable

Deal Size : Not Applicable

Deal Type : Not Applicable

blank